- PharmAust (PAA) has granted $881,085 for a phase one clinical trial of monepantel in patients with Motor Neurone Disease (MND)
- The Australian clinical-stage oncology company specialises in repurposing drugs and its lead candidate monepantel
- PharmAust acknowledges FightMND and its donors, in particular the patients, their families and friends and their support network
- The trial is subject to Institutional Human Research Ethics Committees approval
- PharmAust will retain all intellectual property arising from the trial
- Shares have been trading four per cent higher at 13 cents at 12:27 pm AEST
